A patent portfolio can be legally impressive and commercially disappointing. The real test is not how many patents a business owns, but what those patents enable it to do. For many organisations, patents are still viewed primarily as defensive legal tools. But in today’s innovation-driven economy, the strongest portfolios do much more: they support growth, investment, partnerships, valuation and competitive advantage.
Patents remain important defensive rights. They can deter copying, create barriers to entry and provide leverage when a competitor gets too close. But protection is only the starting point. A portfolio creates real value when it is connected deliberately to the company’s products, markets, funding strategy and commercial relationships. Without that connection, even technically strong patents can become an expensive record of past innovation.
A grant certificate proves that a legal threshold has been met. It does not prove that the patent protects a product customers want, covers a commercially important market or would survive a determined validity challenge.
That distinction matters because patents are expensive throughout their life. Filing, prosecution, overseas protection, translations, renewals and enforcement all compete for capital. The objective should not be to accumulate rights, but to build a portfolio whose scope, ownership and geographic coverage support a credible commercial position.
Nor is quantity a reliable proxy for strength. Five well-chosen patent families may do more for a business than fifty peripheral filings. Value depends on what the claims cover, how difficult they are to design around, whether the rights align with the market and whether the business can use them in practice.
The strongest portfolios are built with the end goal in mind from the beginning.
In my experience, the most productive patent discussions begin not with “Can we patent this?” but with “What commercial position are we trying to create?”
That question changes the conversation. It requires the business to identify the products and services that matter, the markets it expects to enter, the competitors or partners it may encounter and the capabilities that genuinely differentiate it. Filing decisions can then be tested against those objectives rather than driven by technical novelty alone.
This is critical in deep tech: quantum, artificial intelligence, life sciences, semiconductors and advanced engineering, where technologies and business models can evolve faster than the patent process. The portfolio must move with the business - not anchor it to an obsolete roadmap.
The commercial power of a patent is often its ability to create options. For an investor or acquirer, a coherent portfolio can evidence ownership, technical differentiation and a disciplined approach to future growth. It can support valuation, although it does not determine valuation on its own.
Patents can also make collaboration easier. Clearly defined rights help parties understand what each is bringing to a joint development, what access is required and how resulting technology may be commercialised. That clarity can reduce friction in negotiations with larger industrial partners, research institutions and other members of an innovation ecosystem.
Licensing adds another route to value. A business need not manufacture every product or enter every territory itself. Rights that are peripheral to one company’s strategy may be central to another’s. But licensing revenue is not automatic: it depends on market demand, useful claim scope, credible ownership and a counterparty with a commercial reason to take a licence.
A portfolio should not be treated as a museum. Products change, markets close, competitors move and once-promising technologies lose relevance. Regular review is therefore as important as initial filing.
Each patent family should earn its place. Does it still support a current or credible future product? Is the protected market important? Does the right constrain a competitor, strengthen a negotiation or offer a realistic licensing opportunity? Are the likely benefits proportionate to the next round of prosecution and renewal costs?
Where the answer is no, sale, licensing or abandonment may be the disciplined choice. Pruning is not a sign that the original filing failed. It is evidence that the portfolio is being managed as a business asset.
A balanced and credible strategy also recognises what patents cannot do. Patent ownership does not establish freedom to operate: a business may own valuable rights and still risk infringing an earlier third-party patent. Nor is patenting always the best answer. Filing requires disclosure, enforcement can be costly and some innovations are better protected through confidentiality, accumulated know-how, contractual controls, data advantages or speed to market.
The right question is therefore not whether patents are inherently valuable. It is where they add value relative to the alternatives. For some technologies, a patent will be the foundation of market exclusivity. For others, it will be one element in a broader package of rights and practical barriers that competitors cannot easily reproduce.
The strongest patent strategies are neither filing exercises nor defensive reflexes. They are commercial disciplines. They connect protection decisions to products, markets, capital, partnerships and competitive choices - and they change when the business changes.
That means filing selectively, documenting ownership, reviewing the portfolio honestly and being clear about the outcome each right is intended to support. It also means recognising when another form of protection would serve the business better.
The goal is not simply to own patents. The goal is to make the portfolio work for the business.
Looking to get more value from your patents? Talk to our team about developing a patent strategy aligned with your commercial ambitions.
Get expert insights and the top patent stories delivered straight to your inbox.